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The Mental Capacity Act for England and Wales1 was implemented
in October 2007. This legislation aims to empower individuals
who may lose capacity and enable them to plan ahead by making
an advance decision. Advance decisions have the potential to
extend autonomy and provide clinicians and relatives with
reassurance that management is consistent with what the
individual would desire.2 They are likely to be particularly helpful
to individuals with conditions that follow a partially predictable
course such as most neurodegenerative conditions including most
forms of dementia and many other life-shortening conditions.3
There is a lack of information regarding how best to approach
advance decisions and powers of attorney with individuals who
have or are likely to develop conditions that will result in loss of
capacity. We therefore decided to use a qualitative method to
develop a care pathway for advance decisions and powers of
attorney using Huntington’s disease as an exemplar. Most
individuals with this disease will, at some stage, lose capacity to
determine their ongoing care. Timely consideration of advance
decisions seems particularly possible as most individuals with
Huntington’s disease are diagnosed before they lose capacity
and, increasingly, individuals at risk elect to undergo predictive
testing and are aware that they carry the gene before they develop
the disease.
We aimed to address the following issues: when should
advance decisions and lasting power of attorney be discussed;
how should information regarding advance decisions and lasting
power of attorney be delivered and by whom; how should capacity
to execute an advance decision or lasting power of attorney be
determined; and can a care pathway that is acceptable to service
users and clinicians be developed.
Method
A qualitative approach was adopted based on Medical Research
Council guidance.4 A prototype care pathway was developed
through an initial modelling phase which was then piloted and
evaluated. This led to a second prototype which was piloted and
evaluated leading to the final care pathway.
Participants
Modelling phase
Purposive sampling was used to maximise the likelihood of
obtaining a complete range of views. Individuals were invited to
join a stakeholder group to contribute to the pathway develop-
ment. The stakeholders included two individuals with symptoms
of Huntington’s disease, one carer, one asymptomatic individual
who had the altered Huntington’s disease gene, five clinicians
working with individuals with symptoms of the disease, a lawyer
with expertise in this area, a medical ethicist and two advisors
employed by the Huntington’s Disease Association (HDA).
Theoretical sampling was used to ensure involvement of females
and males, individuals of different ages and experience with
different stages of Huntington’s disease.
Pilot phases
During the pilot phases purposive sampling and the ‘snowballing’
technique, whereby those already approached were asked to
identify other individuals who might be approached, were used.
Participants were aged 18 or over, able to provide informed
consent and in active contact with the South Wales Huntington’s
Disease Service. Six individuals with symptoms of the disease,
nine carers/relatives, and four asymptomatic individuals with
the altered Huntington’s disease gene were included.
Recruitment ceased when saturation of themes was achieved.
Data collection
In-depth interviews
In-depth interviews of up to 2 h conducted by J.I.B. were used to
generate data from stakeholders who were service users or carers.
In-depth interviews conducted by V.H. were used to generate data
from individuals involved in the pilot phases.
Focus groups
Four focus groups facilitated by J.I.B. of 1–2 h with group sizes of
between four and eight people were used to generate data from the
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Background
The Mental Capacity Act for England and Wales empowers
individuals to plan ahead for when they may lack capacity.
Aims
To develop a care pathway for advance decisions and
powers of attorney using Huntington’s disease as an
exemplar.
Method
Qualitative study using in-depth individual interviews with
service users and carers, and focus groups with
professionals. Inductive qualitative analysis was used to
develop themes to construct a care pathway that was then
piloted and further evaluated to achieve a final pathway.
Results
A care pathway was developed that incorporated an early
introduction through a formal education session and a
minimum of two sessions separated by at least 2 weeks
before advance decision completion. Optimal delivery of this
intervention requires significant clinical and administrative
commitment.
Conclusions
We have developed a simple, easy-to-follow care pathway
that was acceptable to users and providers.
Declaration of interest
None. Funding detailed in Acknowledgements.
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other stakeholders. Two were conducted in the modelling phase
and one after each pilot phase. Group interaction was encouraged
and individuals were asked to clarify why they thought as they did
to maximise data generation.
Topic guide
A topic guide was used for the in-depth interviews and focus
groups that covered: information to be considered; presentation
of information; methods of delivery; timing issues; individuals
to be involved in the process; methods of communication; method
of assessment of capacity;5,6 and form of documentation.
Individuals interviewed after pilot phase participation were asked
to consider their experience and views of the process.
Analysis
The in-depth interviews and focus groups were audio-taped and
transcribed. Manuscripts were imported into QSR NVivo 7
(QSR International Pty Ltd, 2006) after participant approval.
Relevant themes were identified using grounded theory in which
data collection, analysis and systematic efforts to check and refine
developing themes occurred concurrently.7 The emerging themes
were tested for validity using a variety of recognised techniques8
including discussion of emerging themes; triangulation to
compare the results from different sources; participant review of
emerging themes; exploration of the respondents’ underlying
reasoning; and elements within the data that appeared to
contradict the emerging themes (‘deviant case analysis’).
Results
Modelling phase
The main themes that emerged during the modelling phase could
be grouped into five categories. These are described below and
supported by the quotations of participants in Appendix 1.
Information to be considered and method of delivery
Some confusion was apparent among service users regarding what
advance decisions and powers of attorney are, not least the
difference between advance decisions and euthanasia. Easy-to-
follow, consistent verbal and written information was desired.
Information specific to Huntington’s disease was considered vital,
especially regarding percutaneous endoscopic gastrostomy feeding
and choices about location of care to guide future decisions.
Participants felt that advance decisions would be optimally
introduced through offering a leaflet at a clinic appointment with
a brief verbal explanation. An individual could then choose to
undergo further verbal education backed up by more detailed
written information.
Location and individuals involved
The predominant opinion was that the location is an individual
decision with some preferring their home and others a clinical
setting. Having an established therapeutic relationship with an
expert in Huntington’s disease who facilitated the process emerged
as a dominant theme. Personal qualities such as being approach-
able, caring and sensitive with good communication skills were
felt to be important. Participants also recommended the
additional offer of home visits by an HDA advisor.
Timing and duration of process
Professionals were reluctant to approach service users too early,
particularly asymptomatic individuals with the altered
Huntington’s disease gene, for fear of causing distress. In contrast,
service users had a more positive attitude towards early introduc-
tion of advance decisions in order to increase autonomy. A
consensus was reached that the duration should be flexible
allowing for as many sessions required to reach a decision. It
was also considered important to have a minimum 2-week ‘cool
off ’ period between an initial meeting and advance decision
completion.
Assessment of capacity
Service users and carers felt that capacity assessment was the
responsibility of professionals but it should adhere to legal
requirements. Professionals considered that the assessment should
be decision-specific and adhere to the four levels of capacity stated
in the Mental Capacity Act 2005. Tests such as the MacArthur
Competence Assessment Tool for Treatment (MacCAT–T)9 may
provide additional information to facilitate the assessment but
should not be relied on. It was not felt vital for the capacity
assessor to be from a specific discipline but it should be
acknowledged that many professionals are reluctant to assess
capacity and would require training to feel confident to do so.
Form of documentation
Participants recommended a single, short, easy-to-follow advance
decision form with space for personal statements and wishes. The
main issues that people believed should be on the form were: life-
saving treatments, percutaneous endoscopic gastrostomy feeding,
location of future care, capacity assessment, witness details and a
distribution list. A summary sheet for patient files, and checklists
for education, completion and review were considered important.
As a result of the modelling phase, a prototype care pathway
was developed along with a set of information leaflets and an
advance decision document.
Pilot phases
During the first pilot phase, two individuals with Huntington’s
disease and two asymptomatic individuals with the altered
Huntington’s disease gene completed an advance decision. Two
individuals with the disease decided not to complete an advance
decision after the initial discussion. During the second pilot phase,
one individual with Huntington’s disease and one asymptomatic
individual with the altered Huntington’s disease gene completed
an advance decision. One individual with the disease and one
asymptomatic individual with the altered disease gene decided
not to after the initial discussion.
Involvement in the care pathway was a positive experience for
the majority in both pilot phases. One individual with
Huntington’s disease and their carer described feeling upset for
a few days as a result of discussing end-of-life decisions that
resolved without the need to seek external help. They continued
to consider the care pathway important.
Those who did not complete an advance decision acknowledged
the need for end-of-life issues to be raised to enable choice. For
those who did complete an advance decision they found the
process empowering and described achieving peace of mind
because they were able to make decisions about a future which
would otherwise be completely out of their control. Other benefits
expressed included taking pressure off children, the importance of
choices and gaining more information.
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The themes that emerged are described below and supported
by Appendices 2 and 3.
Information to be considered and method of delivery
General written information on wills and the Mental Capacity Act
was requested along with more Huntington’s disease-focused
information on percutaneous endoscopic gastrostomy feeding.
The power of attorney information was felt to be too detailed
and a single booklet containing all the information provided
recommended.
Location and individuals involved
Participants felt that given limited resources and clinician
availability the formal meetings should take place in a clinical
setting but that all individuals should be offered a home visit from
an HDA advisor. One participant lived some distance from the
hospital and requested an initial telephone interview. Both the
participant and the facilitator were satisfied with the information
delivered and interaction that occurred.
Timing and duration of process
A strong theme emerged that the earlier discussions regarding
advance decisions are introduced the better, subject to checking
personal circumstances and support, to allow consideration of
them before individuals develop symptoms or their symptoms
worsen. The increased difficulty in determining capacity of more
symptomatic individuals was an additional argument for early
introduction.
Form of documentation
The need to fully consider issues around impaired quality of life
when making decisions was the major theme. It was also felt
that the advance decision form should state whether it was
Huntington’s disease-specific or whether it applied whatever the
cause of incapacity. Participants suggested adding statements
concerning organ donation and whether independent legal advice
had been received.
Care pathways and documentation
The emerging themes from the first pilot allowed the development
of the second care pathway (Figs. 1, 2 and 3). A key difference
from the original one was the earlier routine introduction to
everyone including asymptomatic individuals with the altered
Huntington’s disease gene. A statement regarding quality of life
was added to the advance decision documentation to help
individuals who wanted to indicate when they would consider
their quality of life so irreversibly impaired that active treatments
should no longer be given. The results of the second pilot phase
and evaluation led to some minor changes to the documentation
but not the care pathway.
Stage 1 of the care pathway (Fig. 1) shows the introduction of
end-of-life issues (advance decisions and powers of attorney) to
individuals when they attend either pre-symptomatic or symptom
management clinics by a professional with whom they have
already formed a therapeutic relationship. The therapeutic
relationship allows the professional to judge whether it is an
appropriate time to raise this issue. There is an emphasis on
end-of-life issues being a part of routine clinical education, not
least to minimise feelings of it being talked about because of the
severity of disease. The HDA leaflet Huntington’s Disease and the
Law is given, as it provides straightforward definitions of terms.10
Stage 2 outlines the education process and capacity assessment
(Fig. 2). The duration of this stage is variable with a minimum of
two sessions separated by a 2-week ‘cool off ’ period for further de-
liberation and discussion. During the education, all points on the
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Individual x attends pre-symptomatic
or management clinic and has
a rapport with staff member
Individual is emotionally capable
of discussing end-of-life decisions
according to clinical judgement
Yes
End-of-life issues mentioned
as part of routine-clinic
education
Interested
Talk through HDA leaflet
and give individual to take away
No
End-of-life
issues not discussed
Reassess at
next appointment
Review in 2 years
or when appropriatea
No longer
interested
If still in service, review in
2 years or when appropriatea
Not interested
Remains
interested
Arrange appointment with a
member of the Huntington’s Disease
Service who has the time, expertise
and knowledge of the Mental
Capacity Act 2005. Recommend
invitation of other individuals
involved, e.g. relatives,
healthcare proxy
Proceed to
Stage 2
6
6
6
6
6
7
5
6
6
7
5
88
8 8
8
Fig. 1 Stage 1 shows the initial introduction of advance decision and powers of attorney to individuals in the clinic.
HDA, Huntington’s Disease Association.
a. ‘When appropriate’ refers to clinical judgement. An appropriate time will be when symptoms are increasing and individual is at risk of losing capacity in less than 2 years.
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Advance decision completed
Copies to: Individual
Solicitora
Medical notes
General practitioner
Power of attorneya
Healthcare proxya
Othersa
Document in medical roles and care plan
Complete advance decision update sheet, sign and date
Set review date for 2 years’ time or when appropriateb
Inform individual to contact if decision changes or wants
to withdraw and provide Huntington’s Disease Service telephone number
Review in 2 years or when appropriateb
Sign and date review
section on advance
decision form
Sign and date review
form in notes
No change to decision
on advance decision
Process begins again
at start of Stage 2
Individual wants to change
decision on advance decision
6
6
6
6
6
6
5
5
8
7 7
5
Fig. 3 Stage 3 shows the process after completion demonstrating the administrative commitment.
a. If applicable.
b. ‘When appropriate’ refers to clinical judgement. An appropriate time will be when symptoms are increasing and individual is at significant risk of losing capacity in less than 2 years.
Appointment at home or in clinic depending
on individual needs and staff availability
Provide overview of advance decisions.
See education checklist. Deliver according to
clinical judgement. Delivery may take
more sessions
With individual’s permission offer
separate one-to-one discussion with all
present at end-of-education session
Offer further visits or HDA
advisor to discuss further
No further visits or discussion requested
Decision regarding
advance decision completion
Arrange appointment
to attend at least
2 weeks later with
Huntington’s Disease Service
member and provide
list of solicitors for
power of attorney
if desired
Advance decision
completion and
formal capacity
assessment
Explain and advance decision
not completed
Each decision checked
for capacity and recorded
on capacity test sheet
Individual does not
have capacity
Individual has
capacity
Yes
Advance decision signed
and dated by witness
and individual
Proceed to Stage 3
Yes
No
Arrange
appointment
Review in 2 years
or when appropriatea
6
6
6
6
6
6
8
6
7 7
6
77
7
8
5
8 8
7
Fig. 2 Stage 2 shows the education and capacity assessment process.
HDA, Huntington’s Disease Association.
a. ‘When appropriate’ refers to clinical judgement. An appropriate time will be when symptoms are increasing and individual is at significant risk of losing capacity in less than 2 years.
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checklist must be covered and all information provided before a
decision is made. This may take several visits and a visit(s) from
an HDA advisor. When education is complete and a decision to
develop an advance decision formed the decision-specific capacity
assessment can take place. Stage 3 details the completion process
(Fig. 3). Copies are sent to individuals or places requested by
the decision maker. Medical notes and update sheets are then
completed and a review date set.
Discussion
Principal findings
This study produced a care pathway for the introduction and
completion of advance decisions and powers of attorney. Individual
choice and empowerment are emphasised. Optimal delivery requires
significant clinical and administrative commitment.
Strengths and weaknesses
Robust qualitative methodology involving service users, carers and
experts from different backgrounds was employed using
Huntington’s disease as an exemplar for many other conditions.
The pathway was piloted and refined demonstrating its potential
to be implemented into a clinical service. The study involved a
relatively small but usual number of participants for a qualitative
study. Caution is required in generalising the results but we
consider them likely to be broadly representative because of the
strong methodologies including the continuity of recruitment
until there was saturation of themes at each stage of the process.
There is an absence of research concerning the development of
care pathways regarding advance decisions and powers of attorney.
The existing literature provides individual or committee
recommendations that have not been developed through research.
Clinical implications
With the full implementation of the Mental Capacity Act 2005,1
advance decisions will be of increasing importance and need to
be part of the clinical process. This study offers guidance for a
wide range of chronic disease management services. Incorporating
the pathway into routine service provision would be likely to raise
awareness in both staff and service users and increase confidence
in making advance decisions.
There are resource and staff implications that result from such
a process. The average time of education sessions was an hour and
for capacity assessment and decision completion another hour.
Continued review at two-yearly interviews would also lead to
lengthening of appointments. A 2 h+ per person clinician
commitment is likely to be very significant to many services
without accounting for the additional administration required.
Introducing advance decisions may result in adverse
emotional consequences in some individuals. Symptomatic
individuals appeared to be more at risk in this study although
an emotional reaction could occur in anyone. It is, therefore,
strongly recommended that clinicians are aware of this. Early
introduction is likely to be most beneficial but advance decisions
should be raised with any individual with capacity who is affected
by a dementia, other neurodegenerative condition or life-
shortening condition, or who has the adverse result for the altered
gene in the case of Huntington’s disease.
Unfortunately for many people, clinical management decisions
are only considered when they no longer have capacity. One study
found that only 20% of individuals with early dementia were
competent to complete an advance decision.11 This often results
in them never being considered. Other countries have brought
in legislation to counter this. In the USA, providers of care are
required to advise patients of their right to accept or refuse
medical care and to execute an advance decision in the event of
incapacity.12 Several commentators have expressed major ethical
reservations particularly about the meaning, reliability, durability
and portability of advance decisions.13
Some researchers have described a process of advance care
planning in which patients and carers discuss decisions together
before capacity is lost.14 Other key issues include whether an
advance decision made with capacity to refuse treatment should
always take precedence over an acceptance of treatment when
capacity is diminished; what happens when personality alters as
a result of disease resulting in different values; and the impact
of response shift in which individuals adapt to circumstances that
in the advance decision would trigger the denial of treatment.
These can be at least partially ameliorated by appointing a person
with lasting powers of attorney to interpret the advance decision,
or to make decisions on situations the advance decision does not
cover.
Future research
Work is now required to develop an implementation package of
the findings of this study and to monitor the usefulness of the care
pathway when delivered as part of routine clinical care. This
would include production of a booklet containing the educational
materials and a training package for professionals enabling them
to feel confident and competent to deliver the advance decision
pathway and to assess decisional capacity.
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Appendix 1
Quotations associated with the modelling phase
Information to be considered and method of delivery
‘I guess there’s a crossover with euthanasia and people knowing the dif-
ference between them. I think it might be useful to tell people about the
difference between them because I think there might be some confusion.’
A – service user
‘Maybe give people a simplified leaflet that’s just a couple of pages and
then any more details could be discussed at a specific visit with them.’
F – professional
Location and individuals involved
‘I think that it depends on the individual abilities and physical state and
who they have supporting them so that they feel more comfortable. I
mean, if you’re visiting someone in their home then that’s fine, if they’re
used to coming and seeing someone in clinic then that’s probably okay. I
think it would have to be an individual decision depending on the person.’
K – professional
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‘Well, it has to be somebody who is an expert in the disease and that
could be of any discipline but someone who is very versed in the
condition.’ K – professional
Timing and duration of process
‘In order for the individual to have the most control, the discussion should
take place earlier. The earlier the better really.’ H – professional
‘I think if I had symptoms, then I’d be panicking to rush this thing through.’
B – service user
Assessment of capacity
‘Clinical assessment of capacity according to the criteria is the key thing
and that can be done by anyone, but people with more psychiatric conse-
quences may need someone with more expertise.’ K – professional
Form of documentation
‘I would say it should be a standardised document and additional infor-
mation could be filled in by speaking to the person. I’d say that was the
easiest way to do it.’ I – professional
(Letters refer to identity of participant quoted)
Appendix 2
Quotations associated with the first pilot phase
Information to be considered and method of delivery
‘The Huntington’s Disease Association leaflet was actually the best one of
all. It gave a lot of information but it’s not too in-depth either.’ V – service
user
Location and individuals involved
‘I think it would be comfortable if it was made less like a hospital appoint-
ment. It’s not a hospital appointment. It is something very important to us.’
S – carer
‘It helped that we know him. I wouldn’t have wanted someone I didn’t
know. It made it easier. We have a rapport with him.’ Q – carer
Timing and duration of process
‘Even though I went away from here thinking, ‘‘I don’t really need this’’ I
did actually find it useful [2-week ‘cool off’ period]. It made me think.
The two visits were needed.’ B – service user
Form of documentation
‘We weren’t sure about the options on life-threatening conditions. I spoke
to my family about it and we were saying about quality of life. Each of us
had a different opinion on what a decent quality of life is. What we had to
do in the notes was write there what I class as a decent quality of life.
That’s what this is really about, quality of life.’ V – service user
Opinions
‘It’s been exhilarating for me because it’s put my life in order.’ B – service
user
‘I was okay when I was in the room but then when I went away to think
about it that’s when it hit me and I thought about what is to come. I know
I’ve been through it before but it’s the reality of it.’ Q – carer
‘It has been a really positive experience for both of us. There are so many
things to worry about and now that this is done we have one less thing to
worry about.’ S – carer
(Letters refer to identity of participant quoted)
Appendix 3
Quotations associated with the second pilot phase
Information to be considered and method of delivery
‘I think it would be more user-friendly if we had an actual book.’ O –
professional
‘The information in the [HDA] leaflet wasn’t patronising. It was straight to
the point and it was easy to understand.’ C2 – service user
‘It was very good. It was good that the doctor played devil’s advocate, you
know, ‘‘are you sure you want this and do you realise that this will happen
and that.’’ ’ D2 – carer
‘[re telephone call] I thought it was good. I think he has a natural style of
going over things as well and saying I understand that we confirm this and
I think that removes any of the problems like a misunderstanding or things
that you can’t pick up from people’s facial expressions . . . I would
certainly see it as onerous to have to do lots of visits to do this, so being
able to do things over the telephone is a huge advantage.’ Y – service user
Location and individuals involved
‘I did wonder why [he was a psychiatrist]. I suppose because you have to
show that you are thinking rationally . . . It wouldn’t have made any
difference if the genetics nurse had done it as far as I was concerned.
She could have sat there and gone through it.’ D2 – carer
‘I think it helped me having someone that I know explain these things to
me. It needs to be somebody who’s caring when you talk to them. It’s a
major thing to think about really . . . I think somebody who is an expert
in Huntington’s disease would probably be good. I don’t think it has to
be a psychiatrist.’ X – service user
Timing and duration of process
‘I think maybe people might need a bit longer because it’s a big decision
and there’s lots of things to consider and think of. So from my point of
view 2 weeks wasn’t enough . . . Maybe 4 weeks would be good.’ X –
service user
‘That was fine, didn’t need anymore . . . I had all that made up about the
stuff beforehand so for me the two sessions were enough.’ D2 – carer
Assessment of capacity
‘I think it would be fair to say that was the toughest part of it . . . She was
getting really worked up and we had to stop a bit. For her it was difficult . . .
I think the assessment part was the difficult bit because the later on in the
disease you are then the more difficult it is to know what they are saying.’
B2 – carer
Form of documentation
‘Quality of life is very important to be on the form . . . It’s good because it
gives you room for what you want to put down, which is more important
because it’s quite personal what people consider quality of life and what
they want to be treated for . . . Everybody with Huntington’s disease will
want different things for themselves.’ X – service user
‘It was useful to have the sheet of paper with statements [about quality of
life and possible options] because I’m a bit rubbish at that sort of thing.’ D2
– carer
Opinions
‘It’s unfortunate that things like this hadn’t been available for my mother
and my grandmother, having seen them and all the family arguments that
it has caused.’ D2 –carer
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‘For me it was probably better than for her. I know that nobody can
interfere with what we’ve put down. It’s all written down and everybody
knows what the score is.’ B2 – carer
‘Good. It’s what I wanted and it’s done.’ A2 – service user
(Letters refer to identity of participant quoted)
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Knees
For Kate
Stephen Wilson
Everywhere a wasteland of clapped out muscle,
unhinged wheely-bins overflowing with trash;
if you scope the comings and goings,
you’ll find a murky dive,
where inarticulate jerks and low-lifes
meet in an overcrowded space –
a steamy room with loose bodies
locked in unusual positions,
caught on camera, moving slowly,
if at all. A tenor sax bends Mood Indigo
through its horn and behind the bar
a notice tells you not to ask for credit
as a refusal often offends. There are beds
out the back and the floor’s wet, where bits
of ragged tissue have been left around since
something went, after a night on the tiles.
Who knows which gang’s running the protection
racket in those crooked joints, nothing like the bee’s.
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Poems
by
doctors
